Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERCC1/RRM1-Based Adjuvant Therapy in Stage I NSCLC
NCT00792701Phase 2Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- Nov 2008
- Primary completion
- Apr 2016
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of Cisplatin micelle injection (HA132) and gemcitabine in non-small cell lung cancer (NSCLC) (2 arms), sponsored by SWOG Cancer Research Network. Primary endpoint: Feasibility of Pharmacogenomics-based Treatment Assignment at 84 days. Started Nov 2008; status: completed.
02
Drugs
Cisplatin micelle injection (HA132)gemcitabine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00792701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00792701.